Cabaletta Bio Inc. Common Stock (CABA)
Stock · NASDAQ · Health Care
$1.42as of 10/16/2026
Price chart
Active signals
CABA Signal Track Record
How signals performed across all stocks →What CABA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -0.6% | 46% | September 18, 2026 |
| Bollinger Band Breakout | 22 | -5.5% | 36% | September 2, 2026 |
| Bollinger Band BreakdownActive now | 18 | +1.0% | 56% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -3.5% | 20% | September 9, 2026 |
| Any 20-session window (baseline) | -1.7% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 154
- Website
- www.cabalettabio.com/
Fundamentals
- 1-day range
- $1.4$1.62
- Market cap
- $450.03M
- P/E (trailing)
- —
- P/E (forward)
- -1.19
- EPS (trailing)
- $-1.57
- Dividend yield
- —
- Beta
- 3.54
- Avg. volume
- 4.84M
Forecasts
8 analyst ratings
Cabaletta Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CABACabaletta Bio Inc. Common Stock$1.41▼ 9.03%Market cap $450.03MP/E —$1.51$4.23
- KYTXKyverna Therapeutics Inc. Common Stock$5.67▼ 5.03%Market cap $471.16MP/E —$5.61$13.67
- OCGNOcugen Inc. Common Stock$0.78▼ 4.18%Market cap $420.50MP/E —$0.785$2.73
- VALNValneva SE American Depositary Shares$5.61▼ 5.08%Market cap $491.51MP/E —$2.03$5.15
- PROKProKidney Corp. Class A Ordinary Shares$1.33▼ 8.59%Market cap $495.38MP/E —$1.3$3.48
- CCCCC4 Therapeutics Inc. Common Stock$2.77▼ 0.54%Market cap $402.46MP/E —$1.69$5.17
- EIKNEikon Therapeutics Inc. Common Stock$7.42▼ 1.59%Market cap $498.62MP/E —$6.45$17.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CABA Cabaletta Bio Inc. Common Stock | $450.03M | — | $1.41 | ▼ 9.03% | $1.51$4.23 |
| KYTX Kyverna Therapeutics Inc. Common Stock | $471.16M | — | $5.67 | ▼ 5.03% | $5.61$13.67 |
| OCGN Ocugen Inc. Common Stock | $420.50M | — | $0.78 | ▼ 4.18% | $0.785$2.73 |
| VALN Valneva SE American Depositary Shares | $491.51M | — | $5.61 | ▼ 5.08% | $2.03$5.15 |
| PROK ProKidney Corp. Class A Ordinary Shares | $495.38M | — | $1.33 | ▼ 8.59% | $1.3$3.48 |
| CCCC C4 Therapeutics Inc. Common Stock | $402.46M | — | $2.77 | ▼ 0.54% | $1.69$5.17 |
| EIKN Eikon Therapeutics Inc. Common Stock | $498.62M | — | $7.42 | ▼ 1.59% | $6.45$17.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Mark Simon · June 9, 2026 · Grant22.0K
- HENRIQUES RICHARD C JR · June 9, 2026 · Grant22.0K
- Catherine Bollard · June 9, 2026 · Grant22.0K
- Brun Scott C. · June 9, 2026 · Grant22.0K
- Shawn Tomasello · June 9, 2026 · Grant22.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 86.33M
- Total value held
- $199.28M
- Institutional holders
- 108
- Unknown11.08M
- Unknown9.68M
- Unknown8.97M
- Unknown8.83M
- Unknown5.90M
- Unknown5.50M
- Unknown4.03M
- Unknown2.50M
- Unknown2.37M
- Unknown2.18M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Cabaletta Bio Reports Inducement Grants Under Nasdaq Rule
Cabaletta Bio disclosed inducement grants made under Nasdaq Listing Rule 5635(c)(4). This is a standard regulatory filing that provides transparency on equity compensation issued to new employees. The stock is currently trading near its 52-week low, with technical indicators showing moderate selling pressure.
Cabaletta Bio Reports Inducement Grants Under Nasdaq Rule. Cabaletta Bio disclosed inducement grants made under Nasdaq Listing Rule 5635(c)(4). This is a standard regulatory filing that provides transparency on equity compensation issued to new employees. The stock is currently trading near its 52-week low, with technical indicators showing moderate selling pressure.